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Abstract 
 
Background 
 
Human immunodeficiency virus (HIV) infection is now considered a chronic, treatable disease, 
although treatment is associated with increased rates of coronary artery disease (CAD). Screening of 
this at-risk population for CAD remains contentious. The aim of this thesis is to provide some 
guidance into the management of cardiovascular disease in HIV and examine the utility of screening 
CTCA in this population group.  
 
Methods  
 
We set out to disseminate our generated results via publications. The first paper was a literature 
review that sought to provide insight into the management of this complex population, in particular 
focusing on the risk assessment and screening of this population group. The second paper was 
original research; a retrospective single centre analysis that compared the CTCA findings and clinical 
endpoints of a group (n=32) of HIV patients to their uninfected counterparts (n=65), in an effort to 
appraise the efficacy of CTCA in the screening and prediction of adverse cardiac outcomes. 
 
Results 
 
Regarding the literature review we provided a formulaic approach to the risk assessment and 
screening of CAD in HIV. In our research article, patients with HIV were shown to have higher 
prevalence of non-calcified, high risk plaque (0.8±1.5 versus 0.3±0.7, p=0.03), experience greater 
rates of non-ST elevation acute coronary syndromes (ACS) (16% (5) versus 3% (2), p<0.04), but 
paradoxically had lower rates of coronary intervention compared to their uninfected counterparts 
(mean time to event 9.9±3.3 versus 20.6±4.9 months, p<0.04). 
 
Conclusion 
 
Currently there are no guidelines pertaining to the screening and further management of HIV patients 
at risk of CAD. Our literature review outlines a proposed approach for assessing and managing CAD 
in HIV patients. In our clinical research we demonstrated that HIV patients screened with CTCA were 
susceptible to developing at-risk coronary plaques and had higher rates of adverse cardiac events 
despite less frequent invasive coronary intervention compared to HIV negative controls. This thesis 
provides early evidence for the use of CTCA in the screening of HIV patients and highlights a need for 
further investigation to establish appropriate screening and risk assessment protocols as well as more 
rigorous examination of why HIV patients may be less aggressively managed following adverse 
cardiac events. 
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Introduction 
 
 
Human immunodeficiency virus (HIV) infection and Acquired immunodeficiency syndrome (AIDS) 
affects approximately 35 million people globally and is responsible for almost 2 million deaths per 
year.1 In Australia there are 30,000 people living with HIV, representing a prevalence of 0.15%.2 
Nationwide male-to-male sexual contact remains the major route of transmission of HIV,3 and despite 
Australia having both a low incidence and prevalence of HIV compared to many other countries, 
concern has been raised over a recent increase in the annual number of people diagnosed with 
HIV.2,4  
 
With the advent of antiretroviral therapy (ART) morbidity and mortality has improved to a point where 
HIV is now considered a chronic, treatable disease.5 Widespread access to ART has led to non-AIDS 
related events surpassing AIDS related events as the primary source of HIV related disease burden.6 
ART has resulted in an improvement in life expectancy at the expense of chronic age related 
diseases including coronary artery disease (CAD).7,8  
 
Whilst the exact incidence and impact of cardiac disease in Australian patients with HIV is still 
unknown; patients with HIV now have a 1.5-2 fold greater risk of developing CAD compared to non-
infected individuals, with an even greater risk increase conferred to those aged over 45 years.9 
Furthermore, those with HIV typically present with symptomatic disease at a younger age and 
experience higher rates of post-angioplasty restenosis.10,11 Regarding subclinical disease, coronary 
artery plaques have been found to be more prevalent and extensive in HIV-infected men although the 
significance of such findings remains unclear.12,13 
 
HIV and ART’s role in the development of CAD 
 
There is a complex interplay between HIV infection, antiretroviral therapy and the development of 
CAD.  HIV infection itself modestly contributes towards abnormalities in glucose and lipid metabolism, 
with chronic inflammation and immune activation underlying a proatherogenic state.14 In addition, 
traditional cardiovascular risk factors are overrepresented in patients with HIV; owing to a combination 
of population demographics and increased metabolic abnormalities from the use of antiretroviral 
medications.15 While the exact mechanism by which these factors lead to the development of CAD is 
not fully understood, it has been postulated that interference of macrophage and endothelial cell 
function as well as the induction of immunosenescence in T-cells directly by the virus acts 
synergistically with ART induced metabolic dyshomeostasis to lead to accelerated atherosclerosis.16,17 
 
Duration of therapy and individual drug regimens are also factors thought to underlie the increased 
incidence of CAD and myocardial infarction in treated HIV.18,19 It has been suggested that there is an 
increased risk of CAD development with the use of protease inhibitors and some nucleoside reverse 
transcriptase inhibitors. Data however is conflicting, with several large studies disputing this assertion 
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and it is likely that where an association exists, it is drug specific rather than class specific.20-23 
Irrespective, the nature of ART is one of combination therapy with a variety of differing agents and 
classes that change frequently, making delineation difficult in clinical practice. 
 
Myocardial disease in HIV 
 
Although not explicitly pertaining to CAD the interplay between myocardial disease and HIV provides 
a wider comprehension of the disease process and its cardiac implications. The presence of 
myocardial disease in the pre-ART era was widely reported, with high incidences of dilated 
cardiomyopathy as well as systolic and diastolic dysfunction.24 In the contemporary setting with 
unrestricted access to ART there has been a reduction in the prevalence of HIV-related myocardial 
disease although isolated ventricular dysfunction, systolic dysfunction without dilatation and diastolic 
dysfunction have been described.25,26 Whilst studies have shown that most patient with HIV have 
normal cardiac function, there are apparent alterations in systolic and diastolic function suggesting a 
high prevalence of asymptomatic dysfunction.27,28 A nationwide French study found that following 
myocardial infarction HIV patients were more likely to develop symptomatic heart failure than those 
without HIV, suggesting that the combination of underlying cardiac dysfunction and CAD confers a 
greater burden of disease post-infarction in the HIV population.29 
  
The precise pathogenesis of myocardial disease in HIV infection remains ill defined, but is likely to be 
multi-factorial. The direct effects of HIV infection resulting in increased circulating pro-inflammatory 
cytokines, as well as complications from ART and myocarditis from infectious and non-infectious 
causes have been implicated.28  
Screening for CAD in HIV 
 
Despite almost half of all fatal myocardial infarctions occurring in previously asymptomatic patients,30 
controversy still surrounds the role of screening and early management of CAD. With the risk facing 
those with HIV thought to be similar to that of the diabetic population, it has been suggested that 
screening high-risk patients with treated HIV is advantageous to improving outcomes.13,31 However, to 
date no studies have shown a correlation between screening for CAD and an improvement in 
outcomes. The cardiac investigations typically used in the assessment of CAD include stress 
echocardiography, CT coronary angiography (CTCA) and myocardial perfusion scanning.32  
 
CTCA has a sensitivity of 98%, a specificity of 88%, and a negative predictive value of 96-100% in 
ruling out obstructive coronary disease compared to standard invasive angiography.33 Nevertheless, 
at present CTCA has no validated role in the screening of asymptomatic individuals.32,34 CTCA has 
however been used with good effect to assess for CAD in patients with HIV,35 and there is evidence 
that it can aid in risk stratification of asymptomatic patients via coronary artery calcium (CAC) 
scoring.36 Despite this, the utility of CAC scoring alone may be equivocal in the HIV population given 
the differing plaque morphologies and greater rates of higher risk, noncalcified plaque seen in these 
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patients.12 
 
Clinical outcomes of CAD 
 
Acute Coronary Syndrome (ACS) is the most relevant clinical manifestation of CAD. The current 
Australian guidelines for the management of ACS were established by the National Heart Foundation 
of Australia/Cardiac Society of Australia and New Zealand (NHF/CSANZ) in 2006 and have since 
undergone two revisions in 2007 and 2011.37,38 The guidelines are structured around the stratification 
of ACS into ST-elevation myocardial infarction (STEMI) or Non-ST-elevation Acute Coronary 
Syndrome (NSTEACS) with the latter encompassing both Non-STEMI and the angina spectrum. 
NSTEACS can be further stratified into risk groups: high (NSTEACS-HR), intermediate (NSTEACS-
IR), and low (NSTEACS-LR) risk.  
 
A STEMI is defined as either a persistent ST-elevation ≥1 mm in 2 contiguous limb leads; an ST 
elevation ≥2 mm in 2 contiguous chest leads; or a new left bundle branch block pattern. Treatment 
recommendations for STEMI favour Percutaneous Coronary Intervention (PCI) over thrombolysis 
where available within 0–12 hours of symptom onset. Treatment of NSTEACS is variable depending 
on troponin levels at presentation and 6 hours after presentation as well as patient risk group. 
Nevertheless, for all patients with NSTEACS, upgraded medical therapy and cardiac review or 
coronary cardiac unit (CCU) admission is advised. In all but the NSTEAC-IR with a negative stress 
test and NSTEAC-LR, angiography with a view to PCI or coronary artery bypass graft (CABG) is 
recommended in the sub-acute setting.38 
 
Risk stratification plays a key role in assessing a patient with NSTEACS and has been shown to 
improve outcomes.39  However, there is concern that those with HIV are overlooked in the 
assessment of risk in ACS.40,41 
 
Given that baseline risk is what drives the treatment-outcome benefits within a population,42 it is 
logical to surmise that if clinicians attune themselves to the risk profile of their patients, then 
cardiovascular management strategies should be more intensive for those at greater risk. However, 
available evidence suggests that physicians do not always tailor management appropriately to reflect 
the risk profiles of their patients. For example, a number of studies have shown that treatment 
aggressiveness in cardiovascular disease inversely correlates with factors that are markers of poorer 
prognosis, such as age and comorbidity.43,44  
 
Currently HIV is not recognised as a risk factor in in any ACS assessment tools.40 With the propensity 
to develop more at-risk plaques, evidence of greater incidence of ACS and higher rates of post 
angioplasty restenosis; the presence of HIV may be clinically under-recognised as an independent 
risk factor and poor prognostic indicator in ACS.45-48  
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There is an increased risk of CAD and its sequelae facing the contemporary HIV population. Given 
the lack of available clinical data it remains unclear how best to screen and treat this at-risk group. We 
therefore set out to; (a) perform a literature review and provide insight into the management of this 
complex population and (b) undertake original research seeking to compare CTCA findings and 
clinical endpoints in a group of HIV patients in order to appraise the utility of CTCA in the assessment 
of CAD and explore whether these patients are at greater risk of associated morbidity and 
mortality. 
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Abstract 
 
Human immunodeficiency virus (HIV) infection is now considered a chronic, treatable disease, 
although treatment is associated with increased rates of coronary artery disease (CAD). Increased 
risk of CAD in HIV patients has been associated with the inflammatory sequelae of the infection as 
well as the greater prevalence of cardiac risk factors in HIV-positive populations and the side effects 
of life-prolonging antiretroviral therapies. Patients with HIV now have a 1.5-2 fold greater risk of 
developing CAD compared to non-infected individuals, raising the independent risk of CAD in HIV to 
levels similar to those with diabetes. Despite this increased risk, screening and other adjuvant 
assessment tools are lacking.  
 
In this paper we explore the current climate of CAD in the contemporary HIV population and look at 
the tools used in the assessment and management of patients as well as the limitations of these 
approaches for this at-risk population group.   
  
11 
Introduction 
 
Human immunodeficiency virus (HIV) infection and Acquired immunodeficiency syndrome (AIDS) 
affects over 35 million people globally and new infections were estimated at over 2 million in 2014.49 
The number of HIV related deaths continue to decline, with 1.5 million people dying of AIDS related 
cause in 2013, down 35% from the peak in 2005.50 The advent of antiretroviral therapy (ART) has 
improved morbidity and mortality to a point where HIV is now considered a treatable chronic disease.5 
The life expectancy among treated individuals is now comparable to the general population.7 This 
extension in expected survival has resulted in the emergence of chronic diseases including an 
increased incidence of coronary artery disease (CAD).8  
 
Mechanisms of coronary artery disease 
 
Increased risk of CAD in patients with HIV has been associated with the inflammatory sequelae of the 
infection as well as the greater prevalence of cardiac risk factors in HIV-positive populations and the 
side effects of life-prolonging antiretroviral therapies.10,18,51 The underlying pathophysiological 
mechanisms resulting in the increased risk of CAD in patients with HIV are not well understood and 
likely come from a combination of traditional as well as novel risk factors (Figure 1).  While the exact 
impact of cardiovascular disease in patients with HIV is still largely unknown – data remains 
inconsistent due to differences in populations, treatments and study design – CAD has emerged as 
an important cause of mortality and morbidity in those living with HIV.52 
 
  
Figure 1. Multifactorial pathogenesis of increased risk of CAD in treated HIV patients 
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individuals, raising the independent risk of CAD in HIV to levels similar to those who smoke or have 
diabetes.10 Those with HIV and symptomatic CAD present at a younger age and experience a higher 
rate of post-angioplasty restenosis.40 Regarding subclinical disease, coronary artery plaques have 
been found to be more prevalent and extensive in HIV-infected men although the significance of such 
findings remains unclear.12,13 
 
HIV infection and antiretroviral therapy’s implication in cardiac risk  
 
The duration and use of specific antiretroviral drug regimens have been implicated as factors in 
explaining the risk of CAD and myocardial infarction for those with HIV.18,51 Protease inhibitors and 
some nucleoside reverse transcriptase inhibitor are generally thought to increase the risk of CAD 
development, but data has been conflicting.22,23 Several large studies have refuted the association 
between ART classes and CAD.20,21 In particular, the protease inhibitor, ritonavir, and more recently 
the nucleoside reverse transcriptase inhibitor, abacavir, have been implicated in conveying greater 
CAD risk on those with HIV,22,23 although a recent meta-analysis has found no correlation with the 
latter.53 
 
Despite efforts to disentangle which antiretroviral agents are responsible in the development of 
adverse lipid levels and CAD,54 in clinical practice this delineation becomes difficult. The nature of 
ART is one of a combination of multiple agents from a variety of different classes that changes with 
advances in pharmacological research and individual patient circumstances. Therefore, at least from 
a pragmatic standpoint, considering these drugs as a whole entity is perhaps as useful as comparing 
individual drugs and classes. The lipid abnormalities generally seen in patients on ART are increased 
total cholesterol, with decreased HDL and hypertriglyceridemia.55 Hence, it is prudent to note that 
relying on absolute LDL levels in treated HIV patients may underestimate their degree of cardiac risk 
because of concomitant lipid abnormalities.  
 
Management of CAD risk factors in the HIV population 
 
Irrespective of the presence of established heart disease, as a first line all patients with HIV should be 
given recommendations for lifestyle modifications such as smoking cessation, regular exercise, 
weight loss and nutritional advice.56 As with the general population, management of traditional risk 
factors with lifestyle modifications and medications is imperative to slowing the progression of CAD 
and improving clinical outcomes.57 Given that patients with HIV have regular contact with health care 
professionals, there are frequent opportunities to provide counseling and intervention strategies.  
 
Regarding weight, diet and exercise adherence to the national guidelines is encouraged and should 
include a diet high in fruits, vegetables, lean meats and wholegrains along with the avoidance of foods 
high in sugar, saturated fat and salt. >30 minutes of moderate intensity exercise each day is 
recommended along with the maintenance of a healthy weight and waist circumference.58 For patients 
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who smoke both, pharmacological and behavioural smoking cessation strategies should be 
considered.59  
 
Diligent screening and management of diabetes and its complications is essential in HIV positive 
populations.  Current recommendations include a baseline fasting glucose and oral glucose tolerance 
test, with additional screening before and 3-6 months after the commencement of antiretroviral 
therapy that includes a protease inhibitor. In those with identified impaired glucose metabolism, 
meticulous adherence to National Diabetes Management Guidelines is recommended. At minimum, 
this should include yearly (but preferably 3-6 monthly) retinal, foot and urinary albumin screening.15 
Where possible, metabolically favourable antiretroviral drug regimens should also be considered. If 
oral hypoglycaemic drug therapy is required, insulin sensitising agents such as metformin or 
thiazolidinediones are preferred15,60 
 
Lipid lowering recommendations should be based on the current guidelines for lifestyle interventions. 
An initial trial of six weeks of lifestyle modification is appropriate as per the guidelines, prior to the 
consideration of pharmacological intervention.58 At first diagnosis, an initial baseline fasting lipid panel 
should be performed which includes total cholesterol, LDL, HDL and triglyceride levels56,60 
 
Regarding the pharmacological management of lipid profiles, consideration needs to be given to the 
way in which lipid lowering agents interact with anti-retroviral therapy. To varying degrees most statins 
are metabolised in the liver by the CYP34A system, an enzymatic system that some antiretroviral 
have been shown to down regulate.61 Protease inhibitors in particular have been implicated in the 
down regulation of CYP34A and therefore when used in conjunction with statin therapy can lead to 
high serum concentrations and adverse side effects including hepatoxicity and myositis.61  
 
Both atorvastatin and rosuvastatin are effective in reducing LDL and triglyceride levels and neither are 
entirely metabolised by CYP34A, making them more likely to be safe to use in conjunction with 
protease inhibitors than other statins.61 Despite this efficacy, studies assessing the safety of 
rosuvastatin when taken concomitantly with protease inhibitors are conflicting.62,63 Hence, due to its 
high efficacy and low interaction profile, currently atorvastatin is considered to be the first line agent 
for hyperlipidemia management in the HIV patient.61 
 
Assessing Risk of CAD in the HIV population 
 
The ability to provide primary and secondary health intervention has led to the development and 
utilisation of risk assessment tools to direct further investigations and management. These 
assessment tools use regression equations derived from a population sample of the Framingham 
heart and the Framingham offspring studies.64 Although the Framingham risk calculators have been 
shown to predict risk reasonably well, the accuracy of these scores has been shown to vary across 
different population groups.65-67 In patients with HIV, the Framingham risk score underestimates the 
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presence of subclinical atherosclerosis, as well as under-predict rates of myocardial infarction.68,69 
These findings suggest that such tools are unhelpful in this population group where the CAD disease 
process is purportedly complicated by ART, chronic inflammation and oxidative stress on top of pre-
existing conventional risk factors.69,70    
 
Consequently, HIV specific risk assessment tools have emerged. The Data collection on Adverse 
Effects of Anti-HIV Drug Study (DAD) was a prospective multinational cohort study that recruited 
22,625 HIV infected patients.71 The study sought to develop a model that predicted risk of CAD and 
its sequelae. The model includes; age, sex, systolic blood pressure, smoking status, family history of 
CAD, diabetes, total cholesterol, HDL cholesterol and exposure to certain ART. The DAD risk tool 
was found to be more accurate in predicting risk of CAD and myocardial infarction when compared to 
the traditional Framingham risk score in the HIV population.71 
 
Methods for screening CAD in the HIV population 
 
Despite almost half of all fatal myocardial infarctions occurring in previously asymptomatic patients,30 
controversy surrounds the role of screening and early management of CAD. Both the modality of 
screening and timing for when to screen at-risk asymptomatic individuals remains unclear even 
amongst the general population.32 With the risk facing those with HIV thought to be similar to that of 
the diabetic population, where screening is appropriate, screening high-risk patients with treated HIV 
may be advantageous to improving outcomes.31 However, to date no studies have shown a 
correlation between screening for CAD and an improvement in outcomes, making such suggestions 
based on expert opinion rather than being evidence based.  
 
Regarding the modalities used to screen these high-risk patients the cardiac investigations most 
commonly utilised include stress echocardiography, CTCA and myocardial perfusion scanning.32  
 
Stress echocardiography 
 
The role of stress echocardiography in screening asymptomatic people in moderate to high-risk 
populations is well documented, despite no specific data pertaining to those with HIV. Nevertheless, it 
appears reasonable to use stress echocardiography to screen for obstructive CAD in patients with 
HIV.31 This modality however does not provide evidence on mild to moderate coronary disease,72 
which is available through CTCA,73 suggesting stress echocardiography should be used in those with 
optimal medical therapy, where the finding of early vascular disease won’t change management 
(Figure 2). The finding of early atherosclerosis on CTCA enables clinicians to risk stratify and provide 
early intervention for their patients. CTCA allows for insight into early plaque deposition where stress 
echocardiography only identifies patients with established vascular disease.  
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Figure 2. Screening for CAD in HIV patients 
 
Myocardial perfusion scanning 
 
The utility of myocardial perfusion scanning is uncertain due in part to its limited clinical availability. 
Moreover, the use of myocardial perfusion scanning as a first line testing modality for risk stratification 
is currently not recommended in any category of primary prevention subjects.74 Despite this, some 
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target populations.75  
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CTCA allows for an accurate assessment of the location and perfusion of atherosclerotic plaque in the 
coronary artery vasculature.76 It can also gauge the degree of stenosis affecting a coronary vessel, 
determine if a plaque is obstructive or non-obstructive and provide calcium scoring as a surrogate 
measure of calcific CAD.73,77 Currently, 64-slice (or higher) CTCA is the non-invasive modality of 
choice for assessing CAD in a broad spectrum of patients.78-80  
As a clinical tool it has a sensitivity of 98% and specificity of 88% and has been found to be as 
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effective as standard invasive angiography in ruling out obstructive coronary disease.33 With an 
established role in the investigation of intermediate chest pain,81,82 its utility as a screening tool in 
asymptomatic individuals remains contentious. Limited information on the role of CTCA for risk 
assessment in asymptomatic persons is available. A paucity of clinical trials has resulted in the 
current American College of Cardiology Foundation/American Heart Association (ACCF/AHA) 
guidelines not recommending its use in asymptomatic adults (level C evidence).83 There is however 
evidence that CTCA can aid in risk stratification of asymptomatic patients via coronary calcium 
scoring and its role in the screening of asymptomatic high-risk patients is still considered uncertain 
due to insufficient evidence.36,84 Nevertheless, recent evidence has shown that CTCA may be of both 
clinical benefit and is cost effective in the screening of CAD in HIV-positive men.35  
 
Independent of traditional cardiovascular risk factors, coronary plaque, especially noncalcified “soft” 
plaque, is more prevalent and extensive in those with HIV compared to their uninfected counterparts 
(Figure 3).12 The presence of noncalcified plaques on CTCA is associated with greater rates of ACS 
when compared to mixed and calcific plaques.85,86 Given the predominance of high-risk soft plaque 
development, there is growing concern that calcium score alone may not adequately assess HIV 
patients at risk of CAD. Subsequently, CTCA has been considered as the screening tool of choice to 
rule out obstructive disease in patient who have established risk factors.31 Nevertheless, to date there 
are no published trials evaluating the impact of specific therapy on clinical outcomes in patients 
identified as having noncalcified atheroma by CTCA.83  
 
  
Figure 3. (A) CTCA image of a normal left anterior descending (LAD) coronary artery;  
(B) LAD artery with significant plaque burden and differing plaque types as labeled 
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plaque. In those with suboptimal medical management, poor metabolic control or in the case of 
clinician uncertainty regarding management we advocate the use of CTCA in an effort to assess 
burden of disease and dictate the aggressiveness of pharmacological therapy or need for further 
intervention.  
 
Clinical outcomes of CAD 
 
Acute Coronary Syndrome (ACS) is the most relevant clinical manifestation of CAD. ACS 
encompasses either ST-elevation myocardial infarction (STEMI) or Non-ST-elevation Acute Coronary 
Syndrome (NSTEACS) with the latter comprising both Non-STEMI and the angina spectrum.38  
 
Assessing risk in ACS has been shown to be of clinical importance. In NSTEACS risk stratification 
plays a key role in assessing patients and improving outcomes.39 Similarly, recent studies have 
suggested, risk assessment may be used to identify those patients who require coronary care unit 
admission - which has historically been based on criteria for reperfusion therapy rather than absolute 
risk - and in turn improve both the long and short-term clinical outcomes of ACS sufferers.87 However, 
there is concern that those with HIV are overlooked in the assessment of risk in ACS, with evidence 
suggesting that HIV patients are more likely to experience recurrent ACS and restenosis following 
coronary intervention than their uninfected counterparts.40,48 
 
Currently the presence of HIV is not recognised in any ACS risk assessment tools.40 With the 
propensity to develop more at-risk plaques and evidence of greater incidence of ACS, there is 
growing concern that the presence of HIV in symptomatic patients is being neglected.46-48 Failure to 
recognise HIV as a significant independent risk factor in ACS may be responsible for poorer 
outcomes in the acute and sub-acute settings. 
  
Conclusion 
 
There is an increased risk of CAD facing the contemporary HIV population as well as a propensity for 
these patients to develop high-risk coronary plaques. Moreover, because of a lack of available clinical 
data it remains unclear how best to screen and treat this at-risk group. We propose the use of stress 
echocardiography and/or CTCA is appropriate in the screening of moderate to high-risk patients. 
Future studies should look to identify appropriate screening and risk assessment tools and protocols 
for the primary and secondary management of this unique population.
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Abstract  
 
Background 
Human immunodeficiency virus (HIV) infection is now considered a chronic, treatable disease, 
although treatment is associated with increased rates of coronary artery disease (CAD). We set out to 
appraise the utility of CTCA in the assessment of CAD amongst HIV patients and explore whether 
these patients are at greater risk of associated morbidity and mortality compared to HIV-negative 
controls 
 
Methods 
A retrospective, single centred cohort study was undertaken. Data were assessed from 97 males 
without a history of previous coronary artery disease who had undergone CTCA between 2011 and 
2014, including 32 HIV positive and 65 matched HIV negative controls. CTCA were assessed for 
plaque composition. Data on the occurrence of subsequent coronary events and coronary intervention 
was collected. 
 
Results 
Patients with HIV had higher rates of non-calcified plaque (0.8±1.5 versus 0.3±0.7, p=0.03) compared 
to negative controls. At a median follow-up of 38 months, patients with HIV were at greater risk of 
non-ST elevation acute coronary syndrome (16% (5) versus 3% (2), p<0.04), although there was no 
difference in the combined endpoint of all-acute coronary syndromes despite a threefold greater risk 
conferred to those with HIV (19% (6) versus 6% (4), p=0.08). Following baseline CTCA, there was a 
higher rate of coronary intervention in patients without HIV (mean time to event 9.9±3.3 versus 
20.6±4.9 months, p<0.04). 
 
Conclusion 
Patients with HIV have high-risk non-calcified plaque and higher rates of non-ST elevation acute 
coronary syndromes compared to negative controls, but lower rates of coronary angiography and 
intervention following CTCA. Larger prospective studies are needed to confirm if CTCA has a role in 
predicting cardiac events in patients with HIV. The less invasive management in this cohort is also 
worthy of further investigation. 
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Introduction 
 
Human immunodeficiency virus (HIV) infection and Acquired immunodeficiency syndrome (AIDS) 
affects over 33 million people globally and is responsible for almost 2 million deaths per year.1 The 
advent of antiretroviral therapy (ART) has improved morbidity and mortality to a point where HIV is 
now considered a treatable chronic disease.2 The life expectancy among treated individuals is now 
comparable to that of the general population.3 This extension in expected survival has resulted in the 
emergence of chronic age related diseases including coronary artery disease (CAD).4 Increased risk 
of CAD in patients with HIV has been associated with the inflammatory sequelae of the infection as 
well as the greater prevalence of cardiac risk factors in HIV-positive populations and the side effects 
of life-prolonging antiretroviral therapies.5-7 
 
Despite almost half of all fatal myocardial infarctions occurring in previously asymptomatic patients,8 
controversy surrounds the role of screening and early management of CAD in patients with HIV. Both 
the modality of screening and timing for when to screen at-risk asymptomatic individuals remains 
unclear even amongst the general population.9 Screening high-risk patients with treated HIV may be 
advantageous to improve outcomes, 10,11 however, no studies have shown a correlation between 
screening for CAD and an improvement in outcomes, making such suggestions based on expert 
opinion rather than evidence based. 
 
Independent of traditional cardiovascular risk factors, 
coronary plaque, especially non-calcified plaque, has been 
found to be more prevalent and extensive in those with HIV 
compared to their uninfected counterparts.12 Although 
CTCA provides no information regarding functional 
myocardial ischaemia, the presence of non-calcified 
plaques on CTCA in the general population is associated 
with greater rates of ACS when compared to mixed and 
calcific plaques (Figure 1).13-15 Given the predominance of 
high-risk non-calcified plaque development in patients with 
HIV, there is growing concern that calcium score alone may 
not adequately assess patients at risk of CAD who have 
HIV.  
 
We assessed the baseline CTCA and subsequent clinical 
endpoints in a group of HIV patients in order to; (a) 
appraise the utility of CTCA in the assessment of CAD 
amongst HIV patients and (b) explore whether these patients are at greater risk of associated 
morbidity and mortality compared to HIV-negative controls.
 
Figure 1. 
Plaque types on CTCA. Red arrow; 
noncalcific (soft), green arrow; calcific, blue 
arrow; mixed plaques 
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Methods 
 
Patient Selection 
A retrospective single centre observational study at St. Vincent’s Hospital in Sydney, Australia, was 
undertaken. All patients were asymptomatic at the time of CTCA and were screened due to either 
suboptimal medical management, poor metabolic control or in the case of clinician uncertainty 
regarding patient management. A total of 97 patients were recruited. This included 32 HIV positive 
patients who were matched 2:1 for age, sex, Framingham risk, absence of previous coronary artery 
disease and date of scan with 65 HIV negative patients (Figure 2). 
 
Figure 2. Patient selection 
 
Analysis of the CTCA database between 2011 and 2014 (N=2421) identified 43 patients with HIV who 
had undergone CTCA with the stated inclusion criteria. Exclusion criteria included those of non-
English speaking background (NESB, n=1), individuals who were non-contactable or refused consent 
(n=2), those who had previously undergone coronary intervention or had known ischaemic heart 
disease (n=5), and females (n=3; excluded to increase homogeneity of the almost all-male cohort), 32 
HIV positive patients were enrolled and then matched with controls.  
The Human Research and Ethics Committees (HREC) of both St. Vincent’s Hospital and the 
University of Notre Dame approved this study and all patients gave informed consent regarding their 
CTCA database  
(N=2421) 
HIV Positive 
HIV Group (n=32) non-HIV Group (n=65) 
Yes 
(n=43) 
Exclusion Criteria 
Recruited Patients 
(n=32) 
No 
(n=2378) 
Matching Criteria 
Non-Contactable  
Refused Consent 
NESB 
Prior Coronary Intervention 
Female 
Exclusion Criteria 
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participation. 
CTCA Analysis 
A cardiologist experienced in CTCA who was blinded to all patient history including HIV status 
undertook analysis of the scans. The scans were performed on a Toshiba Aquillion 1,320 slice CT 
machine and assessed on a workstation equipped with Vitrea FX software (v.6.7.2).  
As previously validated and described,16,17 the vessels assessed on CTCA were the left main (LM), 
left anterior descending (LAD), left circumflex (LCX) and right coronary arteries (RCA). Arteries were 
assessed in a standard fashion; visually on axial, sagittal and coronal images as well as on 
multiplanar reformats. Each coronary tree was divided into 19 segments,18 and then assessed for the 
number and degree of stenosis, plaque type and the presence of artifact. In addition, each segment 
was individually assessed for the volume of plaque using the Vitrea FX software. Volumes for low 
density non-calcified plaque, high-density non-calcified plaque and calcified plaque were attributed to 
-150-50, 51-150 and >150 Hounsfield’s units respectively and recorded together with each segments 
diameter, length, diameter stenosis, area of stenosis and remodeling index. Automated plaque 
measurements were visually inspected in cross-section at 0.5mm intervals and manual adjustment to 
plaque contours was performed where necessary. Coronary artery calcium scores (CAC) were also 
estimated using previously validated methodology.19 
Clinical Endpoints and Follow Up 
The primary endpoint of the study was the occurrence of an acute coronary syndrome (ACS). ACS 
was considered as any patient who had experienced either; a ST elevation myocardial infarction 
(STEMI) or non-ST elevation acute coronary syndrome (NSTEACS); comprising both non-STEMI and 
the angina spectrum. 
Secondary endpoints included mortality and a composite event pertaining to further management or 
investigations. The composite event consisted of invasive coronary angiogram, percutaneous 
coronary intervention (PCI) or coronary artery bypass grafts (CABG).  
A separate researcher, blinded to patient CTCA results, assessed the HIV status and clinical 
endpoints experienced by the cohort. This consisted of a 10-15 minute telephone survey, which was 
correlated with hospital medical records and the records of treating physicians. Data of deceased 
patients were collected from medical records and death certificates.  
Statistical Analysis 
All analyses were performed using SPSS statistical software (v23).  
Patients were split into two discrete groups; those with HIV and a matched non-infected group (Figure 
2). The specific clinical endpoints of patients with HIV versus those without were then compared. 
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Basic descriptive statistics were used to characterise the demographics and non-continuous variables 
of the cohort. For continuous variables, simple univariate statistics were used. Mann Whitney U tests 
were used to compare continuous variables and Fisher Exact tests for categorical variables.   
Establishing dates for specific endpoints facilitated the use of Kaplan-Meier estimator plots for 
Survival Analyses. Log rank (Mantel-Cox) tests were used to determine mean survival times and the 
degree of statistical significance between groups. Logistic regression analyses were used to assess 
for covariates impacting outcomes. 
Statistically significance was defined at p<0.05. 
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Results 
 
Study Population 
Demographic and clinical features of the cohort (N=97) are presented in Table 1. All patients were 
male and predominantly middle-aged Caucasians. Overall median time to follow-up was 38 months. 
Those without HIV had higher body mass indexes (28 versus 26, p<0.003) and exercised more 
frequently (p<0.005) compared to the HIV population. The HIV group had higher levels of triglycerides 
(2.1 mmol/L versus 1.2 mmol/L, p<0.003). There were no other statistically significant features 
between the two groups including Framingham risk scores. 3 
Table 1. Characteristics of the cohort and their significance 
Characteristic Overall        
(N=97) 
HIV Negative        
(n=65) 
HIV Positive 
(n=32) 
Significance 
(p value) 
Age* (IQR), y  60 (56-64) 60 (56-64) 60 (56-63) NS (0.75) 
Time from CTCA to follow-up* (IQR), m 38 (33-44) 37 (32-44) 39 (33-43) NS (0.86) 
Framingham risk score* (IQR), n 13 (8-16) 13 (8-16) 13 (8-16) NS (0.99) 
Body Mass Index* (IQR), n 27 (24-32) 28 (25-33) 26 (23-29) p<0.003 
Hypertension (%), n  
Anti-hypertensive medication (%), n  
Systolic blood pressure* (IQR), mmHg 
Diastolic blood pressure* (IQR), mmHg 
62 (64) 
60 (62) 
129 (121-140) 
80 (74-86) 
41 (63) 
41 (63) 
130 (123-141) 
80 (75-86) 
21 (66) 
19 (59) 
128 (116-140) 
80 (70-87) 
NS (1.0) 
NS (0.66) 
NS (0.65) 
NS (0.39) 
Hypercholesterolaemia (%), n 
Hypercholesterol medication (%), n 
HDL* (IQR), mmol/L 
LDL* (IQR), mmol/L 
Triglycerides* (IQR), mmol/L 
Total cholesterol* (IQR), mmol/L 
70 (72) 
66 (68) 
1.1 (1.0-1.4) 
2.8 (2.2-3.4) 
1.3 (0.9-2.2) 
4.7 (4.2-5.5) 
45 (69) 
42 (65) 
1.1 (1.0-1.3) 
2.9 (2.0-3.6) 
1.2 (0.9-1.7) 
4.7 (3.9-5.4) 
25 (78) 
24 (75) 
1.2 (1.0-1.5) 
2.7 (2.2-3.4) 
2.1 (1.2-2.7) 
4.8 (4.3-5.6) 
NS (0.62) 
NS (0.48) 
NS (0.88) 
NS (0.88) 
p<0.003 
NS (0.29) 
Diabetes (%), n 
Diabetic medication (%), n  
23 (24) 
21 (22) 
14 (22) 
13 (20) 
9 (28) 
8 (25) 
NS (0.61) 
NS (0.61) 
Smoking* (IQR), py 
Current smoker (%), n 
6 (0-25) 
17 (18) 
8 (0-25) 
9 (14) 
5 (0-25) 
8 (25) 
NS (0.65) 
NS (0.17) 
Family history CAD (%), n  42 (43) 29 (45) 13 (41) NS (0.67) 
Exercise* (IQR), d 2 (1-3) 3 (1-4) 2 (0-3) p<0.005 
Ethnicity 
Caucasian (%), n  
Asian (%), n  
Indian (%), n 
Arabic (%), n  
Maori (%), n 
Latino (%), n 
 
81 (84) 
7 (7) 
2 (2) 
2 (2) 
2 (2) 
1 (1) 
 
56 (86) 
3 (5) 
1 (2) 
2 (3) 
1 (2) 
0 (0) 
 
25 (78) 
4 (13) 
1 (3) 
0 (0) 
1 (3) 
1 (3) 
NS (0.24) 
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y = years, n = number, m = months, py = pack years, d = days/week, IQR = interquartile range, NS = not significant 
* data presented as median 
 
Specific characteristics pertaining to the HIV cohort are presented in Table 2. The HIV group mainly 
consisted of patients with chronic, treated HIV. 30 (94%) patients were on ART at time of follow-up 
with 15 (47%) prescribed ritonavir and 5 (16%) abacavir at the time of follow-up. Almost half (47%) of 
the population had either a previous or current diagnosis of AIDS. 
Table 2. Characteristics of the HIV group 
Characteristic HIV Positive 
(n=32) 
Years since diagnosis* (IQR), y 26 (16-30) 
ART, 
Current ART use (%), n 
Current ritonavir (%), n 
Current abacavir (%), n 
Time on current ART regimen* (IQR), y 
Total time on ART* (IQR), y 
 
30 (94) 
15 (47) 
5 (16) 
7 (4-10) 
19 (14-24) 
HIV serology 
Current CD4* (IQR), x106 cells /L 
Lowest recorded CD4* (IQR), x106 cells /L 
Current viral load, copies/mL 
<20 (%), n 
20-100 (%), n 
101-30,000 (%), n 
>30,000 (%), n 
 
649 (481-851) 
286 (79-378) 
 
28 (88) 
2 (6) 
0 (0) 
2 (6) 
Past/Current AIDS (%), n 15 (47) 
y = years, n = number 
* data presented as medians 
 
The findings and comparison of the CTCA scans are presented in Table 3. The average radiation 
dose was 7.15.5 mSv. Those with HIV had higher non-calcified plaque counts (p=0.03) and ratios of 
calcified to non-calcified plaque (p<0.03). There were no other differences between the groups on 
CTCA including; stenosis score, stenosis count and CAC score. 
Table 3. CTCA findings and their significance 
Characteristic Overall        
(N=97) 
HIV Negative        
(n=65) 
HIV Positive 
(n=32) 
Significance 
(p value) 
Vessel Count* (IQR), n 10 (10-10) 10 (10-10) 10 (10-10) NS (0.49) 
  
13 
Stenosis score* (IQR), n 4 (1-9) 4 (1-7) 6 (1-9) NS (0.59) 
Stenosis count* (IQR), n 4 (1-6) 3 (1-6) 4 (1-6) NS (0.69) 
Plaque count* (IQR), n 
Soft 
Mixed 
Calcific 
 
0 (0-1) 
2 (0-4) 
0 (0-1) 
 
0 (0-0) 
2 (0-4) 
0 (0-1) 
 
0 (0-1) 
2 (0-4) 
0 (0-1) 
 
p=0.03 
NS (0.85) 
NS (0.34) 
Plaque ratio* (IQR), n 
Soft 
Mixed 
Calcific 
 
0 (0-0) 
1 (0-1) 
0 (0-0) 
 
0 (0-0) 
1 (0-1) 
0 (0-0) 
 
0 (0-0) 
1 (0-1) 
0 (0-0) 
 
p<0.03 
NS (0.99) 
NS (0.42) 
Plaque Sum* (IQR), mm3 
Plaque 1, -150-50 HU 
Plaque 2, 51-150 HU 
Plaque 3, >150 HU 
Total plaque 
 
1171 (947-1539) 
1543 (1289-1968) 
490 (262-777) 
3340 (2684-4377) 
 
1171 (994-1533)  
1617 (1354-1933) 
464 (245-755) 
3340 (2734-4157) 
 
1182 (863-1643) 
1453 (1180-2031) 
503 (381-890) 
3242 (2543-4403) 
 
NS (0.74) 
NS (0.47) 
NS (0.27) 
NS (0.86) 
Remodeling index* (IQR), n 1 (1-1) 1 (1-1) 1 (1-4) NS (0.42) 
CAC Agatston score* (IQR), n 95 (0-508) 122 (0-508) 56 (0-545) NS (0.45) 
n = number, HU = Hounsfield’s units NS = not significant 
* data presented as medians 
 
Clinical Outcomes  
At the time of follow-up 3 patients were deceased, 2 from cancer and 1 from sepsis. No deaths were 
from cardiac pathology. Regarding all-cause mortality, 2 patients were from the HIV positive group 
compared to 1 from the HIV negative group (p=0.26). 10 patients had experienced ACS; 7 having 
suffered NSTEACS and 3 a STEMI. 
Acute Coronary Syndrome 
Of the 10 ACS events, 6 occurred in the HIV group and 4 in the control group. The occurrence of 
NSTEACS was significantly higher in the HIV group compared to those without a diagnosis of HIV 
(16% versus 3%, p<0.04). There was a threefold higher incidence of ACS in the HIV group compared 
to the non-HIV group (19% versus 6%), although this was not significant on survival analysis (mean 
time to event 28.3±4.8 versus 33.2±3.9 months, p=0.18, Figure 3).  
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Figure 3. Kaplan-Meier plots for ACS according to HIV status. The plot demonstrates no significance between the rate of 
events in the HIV positive and negative groups (mean time to event 28.3±4.8 versus 33.2±3.9 months, p=0.18) 
 
Intervention 
A total of 20 patients (6 (19%) HIV positive and 14 (22%) HIV negative) had further intervention with 
either invasive angiography, PCI or CABG. A composite endpoint for these procedures was 
significant, with HIV negative patients having undergone adjuvant coronary intervention following 
CTCA sooner than those with HIV (mean time to event 20.6±4.9 versus 9.9±3.3 months, p<0.04, 
Figure 4).  
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Figure 4. Kaplan-Meier plots for Composite Event (CA, PCI, CABG) according to HIV status. The plot demonstrates 
significance between the rate of events in the HIV positive and negative groups (mean time to event 20.6±4.9 versus 9.9±3.3 
months, p<0.04) 
 
In order to assess for compounding covariates, logistic regression analysis was performed. 
Statistically significant variables at baseline which included; body mass index, exercise in days per 
week and triglycerides, as well as other potential confounders such as the use of ritonavir or abacavir 
in those with HIV, age and a family history of cardiovascular disease were all entered into the model. 
These variables were examined and found to not be predictive for the occurrence of either ACS or the 
composite event for cardiac intervention. Similarly, there was no statistically significant correlation 
between the presence of non-calcified plaque and degree of stenosis on ACS. 
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Discussion 
 
This study demonstrates that patients with HIV have greater amounts of non-calcified plaque on 
CTCA and higher rates of NSTEACS, although less timely management with further coronary 
interventions. The data suggest that patients with HIV have increased high-risk plaque which likely 
predicts the increased coronary events and that CTCA may be an appropriate screening tool to 
identify at risk individuals, though further assessment is required.  
 
The presence of non-calcified plaque on CTCA poses a greater risk of ACS in affected individuals,13-15 
and may be a causal factor in the higher rate of NSTEACS observed among our HIV cohort. Our 
results are consistent with the body of evidence demonstrating the higher prevalence of at-risk 
plaques in the HIV population.12,20,21 We now demonstrate this may translates to a greater risk of 
cardiac events in this population. Although no statistical correlation between non-calcified plaque and 
ACS could be found in this study; we believe this is due a lack of statistical power and our findings will 
need to be replicated in a larger investigation.  
 
Recently, Post and colleagues published findings identifying that independent of cardiovascular risk 
factors coronary non-calcified plaque and CAC were more prevalent in an HIV population.12 In our 
study we found that CAC scores were comparable between HIV infected and uninfected individuals. 
CAC scoring provides prognostic information in patients with CAD but its utility in the HIV population 
has been questioned given the higher prevalence of non-calcified plaque.22,23 Although previous 
evidence has identified higher CAC scores in the HIV population,12 a study by Fitch and colleagues 
suggests that higher CAC scores may be due to a greater prevalence of co-morbid metabolic 
syndrome.21 The authors found that patients with HIV infection and metabolic syndrome had 
increased coronary artery calcification when compared to those without metabolic syndrome, and this 
finding was independent of HIV status.21 Our data suggests CTCA is an effective tool in the detection 
of high-risk plaques and that such plaques are more prevalent in the HIV population within whom 
CAC scoring alone may not be of benefit.  
 
Regarding clinical outcomes, the rate of ACS was consistent with previous studies in patients with 
HIV having higher rates of acute myocardial infarction than their uninfected counterparts.24,25 The rate 
of ACS in our population was similar to that found by Freiberg and colleagues who in a cohort of over 
80,000 patients identified that HIV infection carried a 50% increased risk of acute myocardial 
infarction compared to those without HIV.25  
 
While the HIV cohort remains at high risk of CAD, the utility of screening tools for these patients 
remains unclear. Current guidelines suggest there is insufficient evidence to support the use of CTCA 
in any asymptomatic adults.26 Despite this some clinicians advocate CTCA as the tool of choice for 
the assessment of coronary disease in the high-risk HIV population.10,22 To our knowledge ours is the 
first study assessing the correlation between atherosclerosis seen on CTCA and future cardiac events 
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in HIV patients. Although we were unable to present a correlation between plaque type seen on 
CTCA and cardiac outcomes, our findings provide early evidence for the use of CTCA in 
asymptomatic at-risk individuals and warrants further exploration into the utility of CTCA in such a 
cohort. In particular, future studies are required to confirm the relationship between the deposition of 
plaque and ACS in order to determine whether such a correlation exists and if aggressive therapy in 
those with non-calcified plaque will prevent the progression of CAD and its sequelae in this 
population.” 
 
With regard to intervention using coronary angiography, PCI or CABG; patients with HIV were 
managed less aggressively compared to their uninfected counterparts following baseline CTCA. 
Currently there are limited data pertaining to the ongoing assessment and management of CAD in the 
HIV population, however our data parallels less invasive management strategies observed in the 
diabetic population. Alter and colleagues found in a cohort of over 25,000 patients that diabetic 
patients were less likely to receive coronary angiography, PCI and cardiologist follow-up than non-
diabetic patients in the year following an ACS.27 The precise reasons for the paradoxical relationship 
between increased baseline risk and clinician intensity of management is unclear. Evidence suggests 
that clinicians see differences in the efficacy of evidence based therapies and interventions when the 
number of chronic comorbid conditions increases.28 Similarly, uncertainties over the expectations of 
prognostic benefits incurred for patients with chronic disease, coupled with a physician’s aversion 
toward doing harm may alter decision making toward a more conservative approach.27,29 Moreover, 
physicians caring for patients with more than one chronic disease are less attentive to the treatment 
necessities required for managing concurrent disease processes.30  
 
In a multicentre study, Bocarra and colleagues compared the 1-year prognosis of HIV patients to 
uninfected individuals who had experienced an ACS and found HIV infected patients were more likely 
to experience recurrent ACS than those without HIV. Interestingly, they found that PCI in the HIV 
group was prompted by recurrent ACS and more likely to be urgent in nature, which contrasted with 
the uninfected group for whom PCI was largely non-urgent and driven by silent ischaemia.31 Similarly, 
our data show less aggressive management of an at-risk population. We believe the discrepancy may 
be the result of a perceived lower need for invasive procedures in HIV infected patients, due in part to 
the unknown prognosis of the HIV disease itself and therefore less aggressive management by 
treating cardiologists. 
 
There is growing concern that despite their higher risk profile the presence of HIV infection as an 
independent risk in symptomatic patients is being neglected.25,31-33 This may be due to the absence of 
a screening tool that takes HIV infection into consideration when assessing ACS. Cardiovascular risk 
in HIV infected patients is not fully explained by traditional risk factors. The chronic inflammatory 
process of HIV infection, along with antiretroviral therapy evidently accelerates CAD risk.34,35 It 
appears that routine secondary prevention may not take this into account. Nevertheless, given the 
small numbers in our analysis, our results should be interpreted cautiously and further research into 
the treatment of this at-risk population is required in order to confirm whether management and 
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intervention is sub-optimal. 
 
Limitations 
 
When interpreting our findings, a number of limitations need to be considered. Our study was 
retrospective in design and former exposures to risk variables prior to CTCA could not be accurately 
accounted for. This may have an impact on the event rate in either group and possibly skewed the 
presented data. However, the rate of ACS in our study was comparable to event rates in prior studies 
in patients at high-risk of CAD, suggesting that selection bias was not a major confounder to our 
results. Another limitation is that the study was performed on men and any conclusions should not be 
extrapolated to a unisex population. The absence of a correlation between CTCA and clinical 
outcomes is a further limitation of the paper. Our cohort was relatively small with few clinical events 
and we believe that the absence of a correlation between non-calcified plaque and degree of coronary 
stenosis with ACS was due to a lack of statistical power. Our findings will need to be replicated and 
validated in a larger, preferably multicentre investigation. Furthermore, although the time to follow up 
was not significantly different between those with and without HIV, the variability of the range (26-61 
months) presents the potential for confounding as longer follow up times may have allowed for the 
manifestation of more cardiovascular complications. Finally, the significant difference in body mass 
indexes, rate of exercise and triglycerides between those with and without HIV could potentially 
interact with the outcomes. However, logistic regression modeling including these covariates was not 
predictive of ACS or the composite event for cardiac intervention. 
 
Conclusion 
 
CTCA assessed for and identified that those with HIV were susceptible to developing at-risk coronary 
plaques and had higher rates of adverse cardiac events despite less aggressive further coronary 
intervention. The data suggest that HIV patients are at greater risk of CAD independent of traditional 
risk factors and that CTCA is a potential screening tool that may aid early management and reduce 
the burden facing HIV infected patients. The less timely management of patients with HIV needs 
further assessment to determine if this represents suboptimal treatment for a high-risk population.  
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Conclusion 
 
The aim of this thesis was to provide some guidance into the management of CAD in HIV and 
examine the utility of screening CTCA in this population group. Currently there are no guidelines 
pertaining to the screening and further management of this at-risk population. Our literature review 
outlines a proposed approach for assessing and managing HIV patients at risk of CAD.  
 
The review advocates the use of echocardiography and/or CTCA in the screening of high-risk patients 
as well as pharmacological and lifestyle modifications aimed at reducing cardiovascular disease. We 
believe the ability of CTCA to assess plaque-type, degree of obstruction and provide coronary artery 
calcium scoring makes it a beneficial tool when used in the appropriate clinical setting. For HIV 
patients who are optimally medical managed we suggest the use of stress echocardiography to 
assess for life threatening atheroma. However, in those with suboptimal medical management, poor 
metabolic control or in the case of clinician uncertainty we advocate the use of CTCA in an effort to 
assess burden of disease and dictate the aggressiveness of pharmacological therapy or need for 
further intervention. Future studies should look to identify appropriate screening and risk assessment 
tools and protocols for the primary and secondary management of this unique population. 
 
Despite the fact that approximately 50% of fatal myocardial infarctions occur in previously 
asymptomatic patients,30 there remains little consensus about the appropriate screening modalities 
and timing of when to screen at-risk patients. There is limited data pertaining to the use of any 
imaging modalities in the screening of CAD; resulting in the majority of guidelines not recommending 
the use of any imaging modalities for the screening of CAD.32,49,50 Coronary artery calcium scoring is 
one of the few imaging techniques with sufficient data to assess its utility;36,51,52 and some 
international guidelines have subsequently advocated the use of CT derived coronary artery calcium 
scoring in intermediate-risk asymptomatic patients.32 The pitfall with coronary calcium scoring in the 
HIV population is that those with HIV have been shown to have more prevalent and extensive non-
calcified coronary artery plaque,12 likely resulting in an underestimation of sub-clinical disease and 
under prediction of future myocardial infarction. Non-calcific CAD is best assessed via CTCA and is 
considered more high risk than calcific disease,53-55 putting the already vulnerable HIV population at 
even greater risk.  
 
With the recommendations of our review in mind we proceeded to examine the utility of CTCA in the 
screening of HIV patients. Those with HIV had been found to have greater rates of myocardial 
infarction compared to uninfected counterpart,46 and coronary intervention in this population is more 
likely to be emergent in nature and driven by recurrent ACS. Nevertheless, given a paucity of clinical 
trials the current American College of Cardiology Foundation/American Heart Association guidelines 
do not recommend CTCA in asymptomatic adults (level C evidence).50 In our research we present 3 
year data demonstrating that HIV patients screened with CTCA were susceptible to developing at-risk 
coronary plaques and had higher rates of adverse cardiac events despite less aggressive further 
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coronary intervention compared to HIV negative controls.  
 
To our knowledge ours is the first study to assess for a correlation between atherosclerosis seen on 
CTCA and future cardiac events in HIV patients. Our findings provide further support for the use of 
CTCA in the detection of CAD – whilst also identifying its prognostic utility in predicting clinical 
outcomes – therefore strengthening the argument for the use of CTCA in asymptomatic at-risk 
individuals. Nonetheless, further studies are required to confirm the relationship between the 
deposition of noncalcified plaque and ACS in order to determine if aggressive therapy will prevent the 
progression of cardiovascular disease and its sequelae in this population.  
 
We believe our data make a substantial contribution to the literature in this field. It provides early 
evidence for the use of CTCA in the screening of HIV patients and highlights a need for further 
exploration into why this population is less aggressively managed. This discrepancy regarding ACS 
management in HIV may be the result of a perceived lower need for invasive procedures in HIV 
patients, due in part to the unknown prognosis of the disease itself and therefore less aggressive 
management by treating cardiologists. Nevertheless, given the small numbers in our analysis, our 
results should be interpreted cautiously and further research into the treatment of this population is 
needed to confirm whether management and intervention is sub-optimal. 
 
Future research should seek to explore whether current risk assessment tools – in particular the 
Framingham Risk and DAD calculator predict CTCA finding in patients with HIV. A correlation 
between risk assessment tools and CTCA would further support the latter’s use as a screening tool 
and help strengthen guideline recommendations for the assessment and management of CAD in HIV. 
Similarly, a larger prospective trial which sort to examine whether CTCA can predict risk of ACS in 
patients with HIV would further enhance the potential utility of this imaging modality in the assessment 
of asymptomatic patients.  
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Appendices 
Appendix A: Telephone Survey 
 
                                                                            
 
 
 
Introduction 
 
- Good morning/afternoon/evening my name is Dr. James Nadel and I am a researcher from 
the St. Vincent’s Hospital Darlinghurst, may I please speak with (insert participant’s name).  
 
If not available ask if there is a better time to contact the participant and reschedule.  
 
If participant is deceased, apologies for the disruption and re-assure that they will not be contacted 
again regarding this matter. 
 
- I am calling to follow up on a package you were sent a couple of weeks ago asking if you 
were interested in partaking in a survey. 
 
- I was wondering whether you had any questions about the documentation? 
 
Yes            
No           
 
If ‘No’ move to next point 
 
If ‘Yes’ allow the participant to voice questions and respond appropriately 
 
- Are you happy to participate in the survey? 
 
Yes          No 
          
 
If ‘No’ state the following 
 
- On behalf of the St. Vincent’s Hospital and the University of Notre Dame we would like to 
thank you for taking the time to read the documentation and apologies for any 
inconveniences. 
  
If ‘Yes’ move to next point. 
 
- Are you willing to go through the survey with me now it will take between 3-5 minutes?  
 
Yes            
No           
 
If ‘Yes’ state the following 
  
27 
 
- Great, the survey is made up of a number of questions most of which will require a one-word 
answer. I will direct you as we go through it. If at any stage you feel uncomfortable or you 
would like to stop for any reason please let me know. Also, at the end of the survey we ask, if 
you have not already done so to please mail back your consent form in the reply postage paid 
envelope you were sent. If you have lost the form I can mail out another one for you? 
 
If ‘No’ move to the next point  
 
- Can I arrange with you another time to complete the survey? 
 
Yes            
No           
 
If ‘Yes’ arrange a time and date       
 
- Great, I look forward to speaking with you then, if you have any questions please don’t 
hesitate to contact me. In the meantime if you haven’t already done so, may I ask you to mail 
back your consent form in the reply postage paid envelope. If you have lost the form I can 
mail out another one for you? 
 
If ‘No’ state the following 
 
- On behalf of the St. Vincent’s Hospital and the University of Notre Dame we would like to 
thank you for taking the time to read the documentation and apologies for any 
inconveniences. 
 
 
 
 
 
 
************************************************************************************************ 
END OF SECTION 
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Section 1 – Cardiac Risk Factors & Demographics: 
 
1. Have you ever been told you have high blood pressure: 
 
Yes            
No           
Unsure           
 
If ‘No’ or ‘Unsure’ move to Question 3 
 
If ‘Yes’ continue below 
 
2. Do you take medication to manage this? 
 
Yes           
No           
Unsure           
        
3. Have you ever been told you have high cholesterol: 
 
Yes           
No           
Unsure           
 
If ‘No’ or ‘Unsure’ move to Question 5 
 
If ‘Yes’ continue below 
 
4. Do you take medication to manage this? 
 
Yes           
No           
Unsure           
 
5. Have you ever been told you have diabetes: 
 
Yes            
No           
Unsure           
 
If ‘No’ or ‘Unsure’ move to Question 7 
 
If ‘Yes’ continue below 
 
6. Do you take medication to manage this? 
 
Yes           
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No           
Unsure           
7. Have you ever been diagnosed with any other of the following chronic illnesses? 
 
Cancer            
Asthma           
Chronic obstructive airways disease        
Chronic kidney disease         
Hepatitis           
HIV/AIDS           
Cardiomyopathy/Heart Failure         
 
If ‘HIV/AIDS’ continue below otherwise move to Question 11 
 
8. In which year were you diagnosed with HIV? 
 
Year:       
 
9. When was and do you know the results of your most recent viral load and CD4 count? 
 
Date:       
Viral load:       
CD4:        
 
10. Do you know your lowest recorded CD4 count? 
 
Lowest CD4:        
 
11. What is your height (cm) and weight (kg)? 
 
Height:       
Weight:       
 
12. Do you have any family history of heart attacks? 
 
Yes            
No           
Unsure           
 
If ‘No’ or ‘Unsure’ move to Question 13 
 
If ‘Yes’ continue below 
 
13. Which family members? 
 
Mother            
Father            
Brother           
Sister            
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Grandparents/Uncle/Aunty/Other non-1st degree      
 
14. Are you of Caucasian decent? 
 
Yes            
No           
Unsure           
 
If ‘Yes' move to question 12 
 
If ‘No’ or ‘Unsure’ continue below 
 
15. What is your ethnic background? 
 
Ethnicity:       
 
16. How many days of the week do you exercise? 
 
0           
1           
2           
3           
4           
5           
6           
7           
 
17. What is your current tobacco smoking status? 
 
Current smoker          
Ex-smoker           
Never smoked          
 
If “Never smoked” move to Section 2 
 
If “Ex-smoker” continue below then move to Section 2 
 
How many years ago did you quit?       
On average how many cigarettes did you smoke per day (packets)?       
How long did you smoke for (years)?       
 
If “Current smoker” continue below then move to Section 2 
 
On average how many cigarettes do you smoke per day (packets)?       
How long have you been a smoker (years)?       
 
 
 
 
************************************************************************************************ 
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END OF SECTION 
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Section 2 – Chest Pain 
 
1. Have you experienced any chest pain?   
 
Yes            
No           
Unsure           
  
If ‘No’ or ‘Unsure’ move to Question 5 
 
If ‘Yes’ continue below 
 
2. Was this pain dull/crushing in nature? 
 
Yes            
No           
Unsure           
 
3. Was this pain associated with any SOB/palpitations? 
 
Yes            
No           
Unsure           
 
4. Did you seek any medical advice for this?  
 
Yes            
No           
 
If ‘Yes’ please specify 
 
Family doctor (GP)          
Specialist          
Other:            
 
5. Have you ever been admitted to hospital for investigation of chest pain? 
 
Yes            
No           
Unsure           
 
If ‘No’ or ‘Unsure’ move to Question 7 
 
If ‘Yes’ continue below 
 
On what date(s):       
Which hospital(s):       
 
6. Did you receive any medical treatment for this? 
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Yes            
No           
 
If ‘No’ or ‘Unsure’ move to Question 7 
 
If ‘Yes’ please specify 
 
Drugs       
 
Please specify which drugs:       
 
Heart monitoring (ECG or other)         
Coronary stenting      
Balloon angioplasty         
Coronary bypass graft         
Defibrillation           
Other:           
 
7. Have you ever been told you have angina? 
 
Yes            
No           
Unsure           
  
 
8. Have you ever been told you have had a heart attack/myocardial infarction? 
 
Yes            
No           
Unsure           
  
If ‘No’ or ‘Unsure’ move to Section 3 
 
If ‘Yes’ continue below 
 
On what date(s):       
Which hospital(s):       
 
 
 
 
 
 
************************************************************************************************ 
END OF SECTION 
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Section 3 - Medications 
 
1. Please list the medication (if any) you take for blood pressure? 
 
I take:       
I don’t take any medications for blood pressure      
I am unsure if I take any medications for blood pressure     
 
Participant to list above and interviewer to fill below post-survey 
 
ACE inhibitor         
ARB          
CCB          
B-blocker         
A-blocker         
Diuretic          
Other          
 
2. Please list the medication (if any) you take for high cholesterol? 
 
I take:       
I don’t take any medications for cholesterol      
I am unsure if I take any medications for cholesterol     
 
Participant to list above and interviewer to fill below post-survey 
 
Statin           
Ezetimibe          
Other          
  
3. Please list the medication (if any) you take for diabetes? 
 
I take:       
I don’t take any medications for diabetes       
I am unsure if I take any medications for diabetes     
 
Participant to list above and interviewer to fill below post-survey 
 
Insulin          
Biguanide         
Sulfonylurea         
Other          
 
4. Please list the medication (if any) you take for your heart? – these may include blood thinning 
agents (e.g. aspirin, clopidogrel) or heart rate modifying agents 
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I take:       
I don’t take any medications for my heart      
I am unsure if I take any medications for my heart     
 
 
Participant to list above and interviewer to fill below post-survey 
 
Anti-platelet agent        
Chronotropic agent        
Inotropic agents         
Other          
  
 
5. Do you take or have you ever taken any anti-retroviral medications? 
 
Yes            
No           
Unsure           
 
If ‘No’ or ‘Unsure’ move to Section 4 
 
If ‘Yes’ continue below 
 
I take:       
I have taken:        
 
Participant to list above and interviewer to fill below post-survey 
 
Reverse Transcriptase Inhibitors      
NRTI          
NRTI          
Abacavir         
Integrase Inhibitor        
Protease Inhibitor         
Ritonavir        
Entry Inhibitor         
Fusion Inhibitor         
Other          
 
6. How long have you been on your current anti-retroviral regimen? 
 
Years:       
 
7. When did you start anti-retroviral therapy? 
 
Year:       
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************************************************************************************************ 
END OF SECTION 
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Section 4 - Data Retrieval 
 
 
1. Would you allow a researcher from this project to retrieve information about any of the topics 
covered in this survey from your treating doctor or hospital? All data collected will remain 
anonymous and you will not be identifiable in the research’s data or any publications that may 
result from this research.  
 
Yes            
No           
 
If ‘Yes’ please provide details of your (where possible gather name, contact number and address). 
 
9a. Treating doctor:       
9b. Family doctor (GP):       
9c. Specialist:       
9d. Treating hospital:       
 
- That completes the survey. On behalf of the St. Vincent’s Hospital and the University of Notre 
Dame we thank you for taking the time to participate in this survey. If you have any comments 
or questions please don’t hesitate to get in contact with us. I would like to take this time to 
remind you if you haven’t already done so to return your consent form via the mail as soon as 
possible. Thank you again. Have a nice day. 
 
 
 
 
 
 
************************************************************************************************ 
END OF SECTION 
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Appendix B: Plain Language Statement 
 
                                                                            
 
 
Cardiac outcomes in patients following CT or invasive coronary angiography 
 
Dear Sir, 
 
You are invited to participate in the above research project that is being conducted by Dr. Cameron 
Holloway and Dr. James Nadel of St. Vincent’s Hospital. Your name and contact details have been 
gathered from St. Vincent’s Hospital medical records. Analysis of the computer tomography coronary 
angiogram (CTCA) and invasive coronary angiogram (CA) databases has nominated you as a 
potential participant for this study.  
 
The aim of the project is to assess the usefulness of CTCA and CA in the investigation of at-risk 
populations. Your selection for this research does not necessarily mean that you are at greater risk of 
heart problems but that you have undergone one of the two above investigations. With the information 
gathered from this research we hope to help orient future health services around the prognosis and 
screening of patients with coronary angiography.  
 
Participation in this research will take the form of a 3-5 minute telephone survey conducted by our 
researchers. We ask that you please read the forms attached and should you decide to participate in 
the research sign and return the consent form via the reply postage paid envelope that has been 
provided.  
 
You will be telephone contacted by our researcher in approximately 2 weeks to confirm whether or not 
you plan to participate in the project. If you are unsure about any part of the project we ask that you 
withhold from signing and returning the consent form until you are contacted, at which point you will 
be invited to raise any questions you may have.  
 
Your confidentiality and anonymity will be maintained throughout the entirety of the research and your 
participation is wholly voluntary. Furthermore, you have the right to withdraw from the study at 
anytime. Choosing whether or not to participate or choosing to withdraw will not affect your routine 
treatment, your relationship with those treating you or your relationship with the St. Vincent’s Hospital. 
 
The Human Research Ethics Committee of both St. Vincent’s Hospital and the University of Notre 
Dame has approved this project. 
 
Thank you for taking the time to read this documentation please don’t hesitate to contact us with any 
queries. 
 
 
Coordinating Investigator: 
A/ Prof Cameron Holloway 
 
Cardiologist, St. Vincent’s Hospital  
Conjoint Associate Professor of Medicine, 
Victor Chang Cardiac Research Faculty 
 
 
Principal Investigator: 
Dr. James Nadel 
 
Resident Medical Officer, St. Vincent’s 
Hospital 
Masters Student, University of Notre Dame  
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Appendix C: Participant Sheet Information Sheet 
 
                                                                            
 
 
PARTICIPANT INFORMATION SHEET  
 
CLINICAL RESEARCH 
 
 
 
Title 
Cardiac outcomes in patients following CT or invasive coronary 
angiography 
 
Project Sponsor St. Vincent’s Hospital/University of Notre Dame, Sydney 
Coordinating Principal 
Investigator/ Principal Investigator 
A/Prof Cameron Holloway/  
Dr James Nadel 
Location St Vincent’s Hospital, Sydney 
 
 
 
Invitation 
 
You are invited to participate in a research study assessing cardiac outcomes in those who have 
undergone coronary angiography. 
 
Dr James Nadel and A/Prof Cameron Holloway of St. Vincent’s Hospital, Sydney, are conducting the 
study. 
 
Before you decide whether or not you wish to participate in this study, it is important for you to 
understand why the research is being done and what it will involve. Please take the time to read the 
following information carefully and discuss it with others if you wish. 
 
1. ‘What is the purpose of this study?’ 
 
The purpose of the study is to investigate whether coronary angiography is an effective tool in the 
assessment of at risk population groups. By comparing the angiograms of a group of patients to their 
clinical outcomes since undergoing this procedure we hope to better understand how and when these 
techniques should be utilised. Currently the guidelines pertaining to the treatment and screening of 
asymptomatic at risk individuals remains unclear, this is largely due to an absence of clinical 
research. We hope that this research will help orient future health services around the treatment of 
those individuals with cardiac risk factors including high blood pressure, high cholesterol, physical 
inactivity and chronic diseases such as diabetes and HIV.  
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2. ‘Why have I been invited to participate in this study?’ 
 
You are eligible to participate in this study because; you have had a CT coronary angiogram (CTCA) 
or formal coronary angiogram (CA) at St. Vincent’s Hospital and have some degree of cardiac risk.  
 
3. ‘What if I don’t want to take part in this study, or if I want to withdraw later?’ 
 
Participation in this study is voluntary. It is completely up to you whether or not you participate. If you 
decide not to participate, it will not affect the treatment you receive now or in the future. Whatever 
your decision, it will not affect your relationship with the staff caring for you. 
 
If you wish to withdraw from the study once it has started, you can do so at any time without having to 
give a reason. However, it may not be possible to withdraw your data from the study results if these 
have already had your identifying details removed. 
 
4. ‘What does this study involve?’ 
 
Participants in this research will be contacted via telephone and taken through a streamlined 3-5 
minute questionnaire designed specifically for this study. These conversations will NOT be recorded. 
The questionnaire will seek to identify if a participant has experienced any of the outcomes associated 
with cardiovascular disease; their subsequent treatment and clarify their cardiac risk.  
 
In addition to this, participants will be asked to give written consent allowing our researchers to 
access medical records or contact other doctors associated specifically with and limited to issues 
related to their cardiovascular health. This will be undertaken in an effort to attain more accurate data 
for the study.  
 
There is no cost, monitoring or further commitments required of participants in this study following 
completion of the questionnaire. 
 
As a participant in this study you will be asked to take the time to read the consent form in full, sign it 
and return it via the return postage paid envelope. If you have any questions regarding the research 
and your participation please withhold from signing and returning the consent form until you have 
been contacted by the researcher at which point you will be invited to ask any questions you may 
have. 
  
This study will be conducted over an approximate 6-month period from January of 2015. 
 
5. ‘How is this study being paid for?’ 
 
Neither the researchers nor the institutions involved are perceived to benefit financially from the study.  
 
If required, funding will be sought from St. Vincent’s Heart and Lung Centre through Dr Cameron 
Holloway’s special purpose research fund. However the costs of the proposed research are 
anticipated to be minimal.  
 
No member of the research team will receive a personal financial benefit from your involvement in this 
research project (other than their ordinary wages). 
 
6. ‘Are there risks to me in taking part in this study?’ 
 
This research does not involve any interventional treatment. As a result, there are no anticipated 
disadvantages of taking part in this study aside from the time lost partaking in the telephone 
conversation (3-5 minutes) and the returning of the consent form via mail.  
 
If you become upset or distressed as a result of your participation in the research, the researcher will 
be able to arrange for counselling or other appropriate support. Any counselling or support will be 
provided by qualified staff who are not members of the research project team. This counselling will be 
free of charge to participants. 
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7. ‘Will I benefit from the study?’ 
 
This study aims to further medical knowledge and may improve future treatment of cardiovascular 
disease for those with chronic diseases and cardiac risk factors, however it may not directly benefit 
you. 
 
8.  ‘Will taking part in this study cost me anything, and will I be paid? 
 
Participation in this study will not cost you anything. 
 
9.  ‘How will my confidentiality be protected?’ 
 
Of the people treating you, only Dr James Nadel and Dr Cameron Holloway will know whether or not 
you are participating in this study. Any identifiable information that is collected about you in 
connection with this study will remain confidential and will be disclosed only with your permission, or 
except as required by law. Only the researchers named above will have access to your identifiable 
details and results which will be held securely at St. Vincent’s Hospital. If required, only non-
identifiable information will be sent off site. 
 
 
10.  ‘What happens with the results?’ 
 
If you give us your permission by signing the consent document, we plan to compile the data for 
submission to a peer-reviewed journal and/or dissemination at a scientific conference. 
 
In any publication, information will be provided in such a way that you cannot be identified. Results of 
the study will be provided to you, if you wish. 
 
11.  ‘What should I do if I want to discuss this study further before I decide?’ 
 
When you have read this information, Dr James Nadel will discuss it with you and any queries you 
may have. If you would like to know more at any stage, please do not hesitate to contact him/her on 
0411 415 541 or (02) 8382 1111. 
 
12.  ‘Who should I contact if I have concerns about the conduct of this study?’ 
 
This study has been approved by St Vincent’s Hospital HREC. Any person with concerns or 
complaints about the conduct of this study should contact the Research Office who is nominated to 
receive complaints from research participants. You should contact them on (02) 8382 2075 and quote 
LNR/15/SVH/45. 
 
Thank you for taking the time to consider this study. 
If you wish to take part in it, please sign the attached consent form. 
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Appendix D: Participant Consent Form 
 
                                                                            
 
 
CONSENT FORM 
 
Cardiac outcomes in patients following CT or invasive coronary angiography 
 
1. I,………………………..................................of.............................................................................
........................................................................... agree to participate as a participant in the 
study described in the Participant Information Sheet set out above (or: attached to this form). 
2. I acknowledge that I have read the Participant Information Sheet, which explains why I have 
been selected, the aims of the study and the nature and the possible risks of the 
investigation, and the information sheet has been explained to me to my satisfaction. 
3. Before signing this consent form, I have been given the opportunity of asking any questions 
relating to any possible physical and mental harm I might suffer as a result of my participation 
and I have received satisfactory answers. 
4. I understand that I can withdraw from the study at any time without prejudice to my 
relationship to the St. Vincent’s Hospital or my treating doctors. 
5. I agree that research data gathered from the results of the study may be published, provided 
that I cannot be identified. 
6. I understand that if I have any questions relating to my participation in this research, I may 
contact Dr James Nadel on telephone 0411 415 541 or (02) 8382 1111 who will be happy to 
answer them. 
7. I acknowledge receipt of a copy of this Consent Form and the Participant Information Sheet. 
 
Complaints may be directed to the St Vincent’s Hospital Sydney Research Office: 02 8382 2075  
 
Signature of participant        Date 
Signature of witness         Date 
Signature of investigator                   Date 
 
 
Participant will be provided with a copy of the Participant Information Sheet and this Consent Form 
All parties signing the Consent Form must date their own signature 
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Appendix E: Patient Withdrawal Form 
 
                                                                            
 
REVOCATION OF CONSENT 
 
Cardiac outcomes in patients following CT or invasive coronary angiography 
 
I hereby wish to WITHDRAW my consent to participate in the study described above and understand 
that such withdrawal WILL NOT jeopardise any treatment or my relationship with the St. Vincent’s 
Hospital or my medical attendants. 
Signature of participant        Date 
Please PRINT name 
 
The section for Revocation of Consent should be forwarded to 
 
A/Prof Cameron Holloway, 
Heart and Lung Clinic 
Level 4, 
St. Vincent’s Hospital, 
390 Victoria St 
Darlinghurst, 2010 
Ph: (02) 8382 3150 
Email: cameron.holloway@svha.org.au 
 
 
In the event the participant decided to withdraw verbally, please give a description of the 
circumstances. Coordinating Investigator to provide further information here: 
 
 
 
 
Coordinating Investigator to sign the withdrawal of consent form on behalf of a participant if verbal 
withdrawal has been given: 
 
Name of participant        Date 
Signature of investigator 
 
 
 
 
 
Participant will be provided with a copy of this Withdrawal of Consent Form 
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Appendix F: St. Vincent’s Hospital HREC Approval Letter 
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45 
  
  
NB: Dr. C. Holloway is addressed as the principal researcher as per St. Vincent’s Hospital  
requirements, Dr. J. Nadel was responsible for all ethics applications and correspondence pertaining 
to this research.  
   
   
Appendix G: Notre Dame HREC Approval Letter 
 
  
 
NB: Dr. N. Sammel is listed as principal researcher as per UNDA requirements, Dr. J. Nadel was 
responsible for all ethics applications and correspondence pertaining to this research. 
   
   
Appendix H: St. Vincent’s Hospital Ethics Cover Letter 
 
                                                                            
 
 
 
 
Cardiology Department 
 
St Vincent’s Hospital, Darlinghurst 
 
NSW, Australia, 2010 
 
 
Head of Committee 
 
St Vincent’s Hospital HREC 
 
St Vincent’s Hospital, Darlinghurst 
 
NSW, Australia, 2010 
 
 
 
RE: Ethics Proposal 
 
 
Dear Sir/Madam, 
 
My name is Dr James Nadel, I am a Masters Student at the University of Notre Dame. Together with 
A/Prof Cameron Holloway, A/Prof Neville Sammel and the cardiology Department at St Vincent’s 
Hospital, I am hoping to commence research in the field of HIV-related heart disease. 
 
Attached is my low/negligible risk ethics proposal, study protocol, PISCF, plain language statement 
and questionnaire.  
 
Thank you kindly for reviewing this submission.  
 
Please feel free to contact me if there are any queries or concerns. 
 
 
 
Kind Regards, 
Dr. James Nadel 
 
Junior Medical Officer, St. Vincent’s Hospital 
Masters Student, University of Notre Dame, Sydney  
Ph: 0411415541 
Email: james.r.nadel@gmail.com 
 
   
   
Appendix I: Study Protocol 
 
 
                                                                            
 
 
 
 
 
 
 
 
 
 
 
 
Cardiac outcomes in patients following CT or invasive coronary angiography 
 
 
 
Version Number: 1.0 
Date of Protocol: 15/11/2014 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
   
 
1. BACKGROUND 
 
1.1. Disease Background 
 
Coronary plaque is the major cause of coronary artery disease (CAD). Those with HIV are thought to 
be at increased risk of CAD. Currently there are no clear guidelines regarding the screening of at-risk 
asymptomatic patients with HIV. 
 
1.2. Rationale for Performing the Study 
 
With the advent of anti-retroviral therapy, patients with HIV have much greater life expectancies and 
are less susceptible to AIDS related illness. These days, one of the leading causes of death in 
patients with HIV is heart disease, which results from a combination of HIV infection, lifestyle factors 
and the drugs used to treat the virus. The aim of this study is to examine whether those with HIV are 
at greater risk of CAD and its sequelae (compared to risk factor matched controls) and if so; does 
coronary angiography predict this risk. The results of the proposed study may help optimize treatment 
and screening of this specific subgroup.  
 
2. STUDY OBJECTIVES 
 
2.1. Primary Objective 
 
Compare the type and distribution of coronary plaque in patients with HIV to risk factor matched 
controls and assess their clinical outcomes. 
 
3. STUDY DESIGN 
 
3.1. Design  
 
- Retrospective study 
 
3.2. Study Groups 
 
1. Patients with HIV who have had either CT coronary angiograms (CTCA) or formal 
angiograms (CA). 
2. Patients without HIV who have had CTCA or CA and have similar risk profiles in terms of 
traditional risk factors (smoking, diabetes, hypertension, hypercholesterolemia etc.) 
 
3.3. Number of participants 
 
- Approximately 200 
 
3.4. Number of centres 
 
- St Vincent’s Public and Private Hospital 
 
3.5. Duration  
 
- Approximately 6 months 
   
   
 
4. PARTICIPANT SELECTION 
 
4.1. Inclusion Criteria 
 
- Males who have undergone CTCA or CA at St Vincent’s Public and Private Hospital 
 
4.2. Exclusion Criteria 
 
- Follow up <6 months 
- Female 
- <18 years old 
- Non-English speaking background 
- Non-contactable 
- Refused consent 
 
5. STUDY OUTLINE 
 
5.1. Investigation plan 
 
1. Search CTCA and CA database for patients with HIV 
2. Match up patients with risk factor matched controls (2:1) 
3. Blind all study participants from investigators 
4. Analyse and interpret CTCA and CA scans 
5. Follow-up patients for clinical outcomes since angiography (via telephone survey & 
medical records) 
6. Compare clinical outcomes and angiograms between the two groups 
 
5.2. Recruitment and Screening 
 
- Search of CTCA and CA databases 
- Mail out of plain language statement & participant information sheet and consent form 
- Participant consent obtained 
 
5.3. Informed Consent Process 
 
- All patients who participate will provide written consent and can withdraw this consent at any stage 
of the research 
 
6. APPENDIX 
 
6.1. Plain Language Statement 
 
- See attached PLS 
6.2. Participant Information Sheet and Consent Form 
 
- See attached PISCCF 
   
   
 
6.3. Telephone Questionnaire 
 
- See attached questionnaire 
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